MicroRNA‑423‑5p inhibits colon cancer growth by promoting caspase‑dependent apoptosis

Jia,Wenzhuo; Yu,Tao; An,Qi; Cao,Xianglong; Pan,Hongda

doi:10.3892/etm.2018.6288

MicroRNA‑423‑5p inhibits colon cancer growth by promoting caspase‑dependent apoptosis

Authors:
- Wenzhuo Jia
- Tao Yu
- Qi An
- Xianglong Cao
- Hongda Pan
View Affiliations

Affiliations: Department of General Surgery, Beijing Hospital, National Centre of Gerontology, Beijing 100730, P.R. China
Published online on: June 12, 2018 https://doi.org/10.3892/etm.2018.6288
Pages: 1225-1231
Copyright: © Jia et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Plasma microRNA (miR)‑423‑5p is a potential biomarker for the detection of colon cancer. However, the expression and biological role of miR‑423‑5p in colon tumorigenesis remains unclear. In the current study, reverse transcription‑quantitative polymerase chain reaction was used to determine miR‑423‑5p expression in malignant colon tissues and plasma from patients with colon cancer. Cell viability, colony formation and apoptosis assays, as well as western blotting, were performed to investigate the biological role and regulatory mechanisms of miR‑423‑5p in colon cancer. The results demonstrated that miR‑423‑5p expression was downregulated in tumor tissues and plasma from patients with colon cancer, as well as in colon cancer cell lines. Furthermore, overexpression of miR‑423‑5p promoted colon cancer cell apoptosis and resulted in the inhibition of cell proliferation and colony formation. Mechanistically, miR‑423‑5p induced the expression of caspases 3, 8 and 9, as well as p53 in colon cancer. The effect of z‑VAD treatment indicated that the miR‑423‑5p‑mediated colon cancer cell apoptosis is caspase‑dependent. These results suggest that miR‑423‑5p is a tumor suppressor in colon cancer and a potential diagnostic target to enable the early detection of colon cancer.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
2	Jonas S, Thelen A, Benckert C, Spinelli A, Sammain S, Neumann U, Rudolph B and Neuhaus P: Extended resections of liver metastases from colorectal cancer. World J Surg. 31:511–521. 2007. View Article : Google Scholar : PubMed/NCBI
3	Smith JJ, Deane NG, Dhawan P and Beauchamp RD: Regulation of metastasis in colorectal adenocarcinoma: A collision between development and tumor biology. Surgery. 144:353–366. 2008. View Article : Google Scholar : PubMed/NCBI
4	Moore MJ, Scheel TK, Luna JM, Park CY, Fak JJ, Nishiuchi E, Rice CM and Darnell RB: miRNA-target chimeras reveal miRNA 3′-end pairing as a major determinant of Argonaute target specificity. Nat Commun. 6:88642015. View Article : Google Scholar : PubMed/NCBI
5	Slezak-Prochazka I, Durmus S, Kroesen BJ and van den Berg A: MicroRNAs, macrocontrol: Regulation of miRNA processing. RNA. 16:1087–1095. 2010. View Article : Google Scholar : PubMed/NCBI
6	Rupaimoole R, Wu SY, Pradeep S, Ivan C, Pecot CV, Gharpure KM, Nagaraja AS, Armaiz-Pena GN, McGuire M, Zand B, et al: Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression. Nat Commun. 5:52022014. View Article : Google Scholar : PubMed/NCBI
7	Wu SY, Rupaimoole R, Shen F, Pradeep S, Pecot CV, Ivan C, Nagaraja AS, Gharpure KM, Pham E, Hatakeyama H, et al: A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer. Nat Commun. 7:111692016. View Article : Google Scholar : PubMed/NCBI
8	Tajima K, Yae T, Javaid S, Tam O, Comaills V, Morris R, Wittner BS, Liu M, Engstrom A, Takahashi F, et al: SETD1A modulates cell cycle progression through a miRNA network that regulates p53 target genes. Nat Commun. 6:82572015. View Article : Google Scholar : PubMed/NCBI
9	Fang Z, Tang J, Bai Y, Lin H, You H, Jin H, Lin L, You P, Li J, Dai Z, et al: Plasma levels of microRNA-24, microRNA-320a, and microRNA-423-5p are potential biomarkers for colorectal carcinoma. J Exp Clin Cancer Res. 34:862015. View Article : Google Scholar : PubMed/NCBI
10	Lu X and Lu J: The significance of detection of serum miR-423-5p and miR-484 for diagnosis of colorectal cancer. Clin Lab. 61:187–190. 2015. View Article : Google Scholar : PubMed/NCBI
11	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
12	Schmittgen TD and Livak KJ: Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
13	Kumarswamy R, Anker SD and Thum T: MicroRNAs as circulating biomarkers for heart failure: Questions about MiR-423-5p. Circ Res. 106:e8author reply e9. 2010. View Article : Google Scholar : PubMed/NCBI
14	Nabiałek E, Wańha W, Kula D, Jadczyk T, Krajewska M, Kowalówka A, Dworowy S, Hrycek E, Wludarczyk W, Parma Z, et al: Circulating microRNAs (miR-423-5p, miR-208a and miR-1) in acute myocardial infarction and stable coronary heart disease. Minerva Cardioangiol. 61:627–637. 2013.PubMed/NCBI
15	Bauters C, Kumarswamy R, Holzmann A, Bretthauer J, Anker SD, Pinet F and Thum T: Circulating miR-133a and miR-423-5p fail as biomarkers for left ventricular remodeling after myocardial infarction. Int J Cardiol. 168:1837–1840. 2013. View Article : Google Scholar : PubMed/NCBI
16	Luo P, He T, Jiang R and Li G: MicroRNA-423-5p targets O-GlcNAc transferase to induce apoptosis in cardiomyocytes. Mol Med Rep. 12:1163–1168. 2015. View Article : Google Scholar : PubMed/NCBI
17	Stiuso P, Potenza N, Lombardi A, Ferrandino I, Monaco A, Zappavigna S, Vanacore D, Mosca N, Castiello F, Porto S, et al: MicroRNA-423-5p promotes autophagy in cancer cells and is increased in serum from hepatocarcinoma patients treated with sorafenib. Mol Ther Nucleic Acids. 4:e2332015. View Article : Google Scholar : PubMed/NCBI
18	Wan Y, Fei X, Wang Z, Jiang D, Chen H, Wang M and Zhou S: miR-423-5p knockdown enhances the sensitivity of glioma stem cells to apigenin through the mitochondrial pathway. Tumour Biol. 39:10104283176955262017. View Article : Google Scholar : PubMed/NCBI
19	Dai L, Cui X, Zhang X, Cheng L, Liu Y, Yang Y, Fan P, Wang Q, Lin Y, Zhang J, et al: SARI inhibits angiogenesis and tumour growth of human colon cancer through directly targeting ceruloplasmin. Nat Commun. 7:119962016. View Article : Google Scholar : PubMed/NCBI
20	Offit K, Kohut K, Clagett B, Wadsworth EA, Lafaro KJ, Cummings S, White M, Sagi M, Bernstein D and Davis JG: Cancer genetic testing and assisted reproduction. J Clin Oncol. 24:4775–4782. 2006. View Article : Google Scholar : PubMed/NCBI
21	Calvert PM and Frucht H: The genetics of colorectal cancer. Ann Intern Med. 137:603–612. 2002. View Article : Google Scholar : PubMed/NCBI
22	Wei EK, Wolin KY and Colditz GA: Time course of risk factors in cancer etiology and progression. J Clin Oncol. 28:4052–4057. 2010. View Article : Google Scholar : PubMed/NCBI
23	Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
24	O'Connell MJ: Oxaliplatin or irinotecan as adjuvant therapy for colon cancer: The results are in. J Clin Oncol. 27:3082–3084. 2009. View Article : Google Scholar : PubMed/NCBI
25	Dienstmann R, Salazar R and Tabernero J: Personalizing colon cancer adjuvant therapy: Selecting optimal treatments for individual patients. J Clin Oncol. 33:1787–1796. 2015. View Article : Google Scholar : PubMed/NCBI